Overview
Compare with RenovoRx, Inc., SeaStar Medical Holding Corp or Sintx Technologies, Inc., or pick any stock.
- TickerPETV on OTC1
- IndustrySurgical & Medical Instruments & Apparatus1
- HeadquartersEdina, Minnesota1
- Incorporated inNV3
- Business address5251 Edina Industrial Blvd, Edina, Mn 554393
- Filer category, Emerging growth company3
See how the biggest companies compare on our leaderboards
Agreement”), to market, distribute and sell the Company’s products in the United States, including the District of Columbia.4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2026
66.1%Gross margin2
-793.9%Operating margin2
-917.4%Net margin2
0.8%Revenue growth, 20262
-476.2%Return on equity2
-$6.1MFree cash flow2
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Sales to Vedco brought in 95% of the revenue PetVivo Holdings, Inc. broke down this way in fiscal 2026.
Products and services by year
| Products and services | 2025 | 2026 |
|---|---|---|
| Sales to Vedco | $288.9K | $809.2K |
| Sales To Clipper | $194.5K | $40.5K |
Where the money goes
Where each dollar of revenue went, fiscal 2026
- Cost of revenue21¢$386.9K
- Research and development78¢$1.4M
- Interest1¢$12.7K
Out of $1.1M in revenue.2 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.2
| Period ending | 2026-03-31 | 2025-03-31 |
|---|---|---|
| Revenues | $1.1M | $1.1M |
| Cost of Sales | $386.9K | $137.7K |
| Gross Profit | $754.8K | $994.9K |
| Sales and Marketing | $3.1M | $2.6M |
| Research and Development | $1.4M | $1.6M |
| General and Administrative | $4.3M | $4.8M |
| Impairment Expense | $1.0M | |
| Total Operating Expenses | $9.8M | $9.1M |
| Operating Loss | -$9.1M | -$8.1M |
| Loss on Disposal of Assets | -$149.1K | |
| Gain on Extinguishment of debt | $66.1K | |
| Unrealized Loss on Change in Derivative Liabilities | -$320.4K | -$106.5K |
| Other Income | $111.5K | $56.4K |
| Interest Income | $13.1K | |
| Interest Expense | -$1.1M | -$359.4K |
| Total Other Income (Expense) | -$1.4M | -$343.4K |
| Loss before taxes | -$10.5M | -$8.4M |
| Net Loss | -$10.5M | -$8.4M |
| Less: Series B Preferred Stock Dividends | -$403.6K | |
| Net Loss Available to Common Stockholders | -$10.9M | -$8.4M |
| Basic | -$0.38 | -$0.41 |
| Diluted | -$0.38 | -$0.41 |
| Basic | 30.2M shares | 20.5M shares |
| Diluted | 30.2M shares | 20.5M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.2
| Period ending | 2026-03-31 | 2025-06-30 | 2025-03-31 | 2024-03-31 |
|---|---|---|---|---|
| Cash | $200.8K | $227.7K | ||
| Accounts receivable, net of allowance for credit losses | $100.8K | $60.6K | ||
| Subscriptions receivable | $600.0K | $4.4M | ||
| Inventory, net of allowances (Note 2) | $538.4K | $323.5K | ||
| Investments | $150.0K | $150.0K | ||
| Prepaid expenses and other current assets (Note 3) | $269.9K | $447.8K | ||
| Total Current Assets | $1.9M | $5.6M | ||
| Property and Equipment, net (Note 4) | $448.9K | $766.9K | ||
| Operating lease right-of-use | $54.7K | $891.0K | $961.5K | |
| Patents and trademarks, net (Note 5) | $20.5K | $23.7K | ||
| Licensing Agreements, net (Note 6) | $1.2M | $1.9M | ||
| Security deposit | $12.8K | $27.5K | ||
| Total Other Assets | $1.3M | $3.0M | ||
| Total Assets | $3.6M | $9.3M | ||
| Accounts payable | $547.4K | $821.1K | ||
| Accrued expenses (Note 7) | $453.7K | $948.6K | ||
| Operating lease liability current portion | $54.7K | $163.8K | ||
| Notes payable and accrued interest-current portion (Note 8) | $321.4K | $312.9K | ||
| Convertible notes payable and accrued interest, net of debt discount of $0 and $149,644 (Note 9) | $1.6M | |||
| Derivative liabilities | $448.1K | |||
| Total Current Liabilities | $1.4M | $4.3M | ||
| Operating lease liabilities (net of current portion) | $797.7K | |||
| Notes payable and accrued interest (net of current portion) (Note 8) | $5.4K | |||
| Total Other Liabilities | $803.1K | |||
| Total Liabilities | $1.4M | $5.1M | ||
| Common stock, par value $0.001 per share, 250,000,000 shares authorized, 35,849,919 and 24,181,537 shares issued and outstanding at March 31, 2026 and 2025 | $35.9K | $24.2K | ||
| Common stock to be issued | $649.8K | |||
| Additional Paid-In Capital | $103.6M | $95.4M | ||
| Accumulated Deficit | -$102.1M | -$91.2M | ||
| Total Stockholders Equity | $2.2M | $4.2M | $686.0K | |
| Total Liabilities and Stockholders Equity | $3.6M | $9.3M | ||
| Convertible notes payable and accrued interest, discount | $0 | $149.6K | ||
| Preferred stock, par value | $0.00 | $0.00 | ||
| Preferred stock, shares authorized | 20.0M shares | 20.0M shares | ||
| Common stock, par value | $0.00 | $0.00 | ||
| Common stock, shares authorized | 250.0M shares | 250.0M shares | ||
| Common stock shares issued | 35.8M shares | 24.2M shares | ||
| Common stock, shares outstanding | 35.8M shares | 24.2M shares |
| Period ending | 2026-03-31 | 2025-06-30 | 2025-03-31 | 2024-03-31 |
|---|---|---|---|---|
| Cash | $200.8K | $227.7K | ||
| Accounts receivable, net of allowance for credit losses | $100.8K | $60.6K | ||
| Subscriptions receivable | $600.0K | $4.4M | ||
| Inventory, net of allowances (Note 2) | $538.4K | $323.5K | ||
| Investments | $150.0K | $150.0K | ||
| Prepaid expenses and other current assets (Note 3) | $269.9K | $447.8K | ||
| Total Current Assets | $1.9M | $5.6M | ||
| Property and Equipment, net (Note 4) | $448.9K | $766.9K | ||
| Operating lease right-of-use | $54.7K | $891.0K | $961.5K | |
| Patents and trademarks, net (Note 5) | $20.5K | $23.7K | ||
| Licensing Agreements, net (Note 6) | $1.2M | $1.9M | ||
| Security deposit | $12.8K | $27.5K | ||
| Total Other Assets | $1.3M | $3.0M | ||
| Total Assets | $3.6M | $9.3M | ||
| Accounts payable | $547.4K | $821.1K | ||
| Accrued expenses (Note 7) | $453.7K | $948.6K | ||
| Operating lease liability current portion | $54.7K | $163.8K | ||
| Notes payable and accrued interest-current portion (Note 8) | $321.4K | $312.9K | ||
| Convertible notes payable and accrued interest, net of debt discount of $0 and $149,644 (Note 9) | $1.6M | |||
| Derivative liabilities | $448.1K | |||
| Total Current Liabilities | $1.4M | $4.3M | ||
| Operating lease liabilities (net of current portion) | $797.7K | |||
| Notes payable and accrued interest (net of current portion) (Note 8) | $5.4K | |||
| Total Other Liabilities | $803.1K | |||
| Total Liabilities | $1.4M | $5.1M | ||
| Common stock, par value $0.001 per share, 250,000,000 shares authorized, 35,849,919 and 24,181,537 shares issued and outstanding at March 31, 2026 and 2025 | $35.9K | $24.2K | ||
| Common stock to be issued | $649.8K | |||
| Additional Paid-In Capital | $103.6M | $95.4M | ||
| Accumulated Deficit | -$102.1M | -$91.2M | ||
| Total Stockholders Equity | $2.2M | $4.2M | $686.0K | |
| Total Liabilities and Stockholders Equity | $3.6M | $9.3M | ||
| Convertible notes payable and accrued interest, discount | $0 | $149.6K | ||
| Preferred stock, par value | $0.00 | $0.00 | ||
| Preferred stock, shares authorized | 20.0M shares | 20.0M shares | ||
| Common stock, par value | $0.00 | $0.00 | ||
| Common stock, shares authorized | 250.0M shares | 250.0M shares | ||
| Common stock shares issued | 35.8M shares | 24.2M shares | ||
| Common stock, shares outstanding | 35.8M shares | 24.2M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.2
| Period ending | 2026-03-31 | 2025-03-31 |
|---|---|---|
| Net Loss | -$10.5M | -$8.4M |
| Stock-based compensation | $1.9M | $1.1M |
| Depreciation and amortization | $511.5K | $174.6K |
| Amortization of Right-of-Use Asset | $31.4K | $178.6K |
| Unrealized loss on change in fair value of derivatives | $320.4K | $290.6K |
| Loss on disposal of fixed assets | $149.1K | |
| Loss on impairment of licensing agreement | $1.0M | |
| Loss on write down of inventory | $239.9K | |
| Amortization of debt discount | $936.6K | $106.5K |
| Common stock issued for services | $192.7K | $574.3K |
| Stock issued in lieu of compensation, net of cancelled shares | $359.5K | |
| Common stock issued for stock option buyout program | $72.8K | |
| Gain on extinguishment of debt | -$66.1K | |
| Loss on sale of lease vehicles | $1.0K | |
| (Increase) decrease in prepaid expenses and other assets | $177.9K | $97.7K |
| (Increase) decrease in accounts receivable | -$45.1K | -$41.9K |
| (Increase) decrease in inventory | -$454.8K | $66.6K |
| (Decrease) increase in accounts payable and accrued expenses | -$649.0K | $271.4K |
| Lease liabilities | -$31.4K | -$179.6K |
| Accrued interest in notes payable | $107.4K | $63.6K |
| Net Cash (Used In) Operating Activities | -$6.1M | -$5.3M |
| Purchase of property and equipment | -$7.7K | -$63.4K |
| Payments received on disposal of equipment | $4.9K | |
| Payments made on licensing agreement | -$500.0K | |
| Security deposits | $14.7K | |
| Net Cash Provided by (Used In) Investing Activities | $11.8K | -$563.4K |
| Proceeds from the sale of common stock and warrants | $675.0K | $2.1M |
| Proceeds from exercise of warrants | $1.8M | |
| Proceeds from preferred stock subscription receivable | $4.4M | |
| Proceeds from the issuance of convertible debentures | $160.0K | $1.9M |
| Proceeds from the exercise of warrants | $851.8K | |
| Proceeds from the issuance of notes payable | $332.0K | $300.0K |
| Repayments of notes payable | -$350.2K | -$7.4K |
| Net Cash Provided by Financing Activities | $6.1M | $6.0M |
| Net increase (decrease) in Cash | -$26.9K | $140.3K |
| Interest | $21.8K | $8.4K |
| Derecognition and decrease of operating lease right-of-use asset and lease liability | -$891.0K | |
| Common stock issued on conversion of convertible notes and accrued interest | $2.0M | $301.6K |
| (Decrease) increase to operating lease right of use asset and operating lease liabilities | -$53.2K | |
| Vesting of restricted stock units | $175 | $428 |
| Stock issued for conversion of accounts payable | $6.0K | |
| Dividends declared on Series B preferred stock | $403.6K | |
| Stock issued for conversion of accrued dividends | $278.6K | |
| Stock issued for licensing agreement | $800.0K | $1.0M |
| Stock issued for investment | $150.0K | |
| (Decrease) increase to accrued expenses for licensing agreement | -$125.0K | $500.0K |
| Warrants issued as debt discount | $98.7K | |
| Derivative liabilities as debt discount | $341.6K | |
| Stock to be issued for common stock subscription receivable | $600.0K | |
| Preferred stock subscription | $4.4M |
No quarter-by-quarter statement was filed.
Corporate structure
PetVivo Holdings, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of PetVivo Holdings, Inc.
- A.L. Sarroff Fund, LLC Filed SCHEDULE 13D/A on PetVivo Holdings, Inc., latest Sep 15, 2026 (15 filings since Aug 21, 2023)
- Alex Nazarenko Filed SCHEDULE 13G on PetVivo Holdings, Inc., latest Aug 5, 2026 (2 filings since Nov 4, 2024)
- Stanley C. Cruden Filed SCHEDULE 13G/A on PetVivo Holdings, Inc., latest Jan 20, 2026 (19 filings since Jan 28, 2022)
- John F. Dolan Filed SC 13D/A on PetVivo Holdings, Inc., latest Jun 23, 2022
- John Lai Filed SC 13D/A on PetVivo Holdings, Inc., latest Jun 23, 2022
- Randall A. Meyer Filed SC 13D on PetVivo Holdings, Inc., latest Jun 23, 2022
- PetVivo Holdings, Inc. Edina, Minnesota
Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What PetVivo Holdings, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $1.1M2 Mar 31, 2026 | $1.3M2 Mar 31, 2025 | −19.4% |
| Accumulated depreciation | $608.9K2 Mar 31, 2026 | $545.8K2 Mar 31, 2025 | +11.6% |
| Property and equipment, net | $448.9K2 Mar 31, 2026 | $766.9K2 Mar 31, 2025 | −41.5% |
| Operating-lease assets (leased space) | $54.7K2 Mar 31, 2026 | $961.5K2 Mar 31, 2025 | −94.3% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Marketable securities, current | $150.0K2 Mar 31, 2026 | $150.0K2 Mar 31, 2025 | 0% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Finite-lived intangibles, gross | $3.9M2 Mar 31, 2026 | $3.9M2 Mar 31, 2025 | 0% |
| Accumulated amortization | $3.9M2 Mar 31, 2026 | $3.9M2 Mar 31, 2025 | +0.1% |
| Finite-lived intangibles, net | $20.5K2 Mar 31, 2026 | $23.7K2 Mar 31, 2025 | −13.6% |
| Patents, net | $3.9M2 Mar 31, 2026 | $3.9M2 Mar 31, 2025 | 0% |
| Licenses, net | $2.8M2 Mar 31, 2026 | $2.0M2 Mar 31, 2025 | +40.0% |
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $538.4K2 Mar 31, 2026 | $323.5K2 Mar 31, 2025 | +66.4% |
| Raw materials | $225.3K2 Mar 31, 2026 | $260.2K2 Mar 31, 2025 | −13.4% |
| Work in process | $21.9K2 Mar 31, 2026 | $41.5K2 Mar 31, 2025 | −47.4% |
| Finished goods | $291.2K2 Mar 31, 2026 | $21.8K2 Mar 31, 2025 | +1237.0% |
Properties, in its own words
We do not own any real estate. We lease approximately 3,600 square feet of office, laboratory, and warehouse space at 5251 Edina Industrial Blvd., Edina, Minnesota. This lease will expire in November 2026.
In January 2022, we leased an additional 2,400 square feet of office space near the location above. This lease will expire in March 2027. Refer to Note 9. Commitments and Contingencies, in the Notes to Consolidated Financial Statements set forth in Part II, Item 8. Financial Statements and Supplementary Data of this Annual Report, for further information regarding our leases.
The rest of Item 2
On January 10, 2023, the Company entered into a new lease agreement for 14,073 square feet of production and warehouse space with a commencement date of April 1, 2023, which is when the control and right of use for this lease asset took place. The initial monthly base rent was $8,420 and had annual increases of 2.5%. The Company was also responsible for its proportional share of common space expenses, property taxes, and building insurance. The lease had a termination of June 30, 2033, and the Company had a renewal option for a period of five years. The Company terminated its ten-year lease agreement on the 14,073 square foot production and warehouse space effective June 30, 2025.
The Company believes that the current facilities are suitable and adequate to meet the Company’s current needs and that suitable additional space will be available as and when needed on acceptable terms.
Item 2 of the 10-K filed Jun 29, 2026.4
Leadership
Who has led PetVivo Holdings, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chair
Chief financial officer
Chief operating officer
201520202025
- Chief executive officerWesley Hayne Sep 19, 2018 to Sep 19, 201814
- Chief executive officerJohn Lai Mar 28, 2014 to Sep 19, 201815
- ChairJohn Lai Sep 19, 2018 to Sep 19, 201816
- PresidentDavid B. Masters Jun 8, 2015 to Jun 8, 201517
- PresidentJohn Lai Mar 28, 2014 to Sep 19, 202415
- Chief financial officerGarry N. Lowenthal Mar 20, 2024 to Oct 18, 202418
- Chief financial officerDiane M. Levitan Oct 18, 2024 to Oct 18, 202419
- Chief financial officerJohn Spencer Breithaupt Oct 18, 2024 to Oct 18, 202420
- Chief financial officerJoseph William Jasper Oct 18, 2024 to Oct 18, 202421
- Chief financial officerMichael Eugene Eldred Oct 18, 2024 to Oct 18, 202422
- Chief financial officerRobert J. Costantino Oct 18, 2024 to Oct 18, 202423
- Chief financial officerRobert James Rudelius Oct 18, 2024 to Oct 18, 202424
- Chief financial officerRobert J. Folkes May 3, 2021 to Oct 20, 202225
- Chief financial officerJohn Michael Carruth Jun 4, 2019 to Sep 22, 202026
- Chief financial officerJohn Lai Sep 19, 2018 to Sep 19, 201816
- Chief financial officerJohn F. Dolan Mar 28, 2014 to Aug 20, 201427
- Chief operating officerJohn Lai Sep 10, 2021 to Sep 10, 202128
- Chief operating officerRandall A. Meyer Jun 8, 2015 to Sep 19, 202429
Board members and other officers (20)
- SecretaryJohn F. Dolan Nov 18, 2019 to Sep 19, 202430
- Board memberJoshua David Ruben Nov 19, 2025 to now31
- Board memberMichael Eugene Eldred Oct 8, 2024 to now32
- Board memberJohn Spencer Breithaupt Apr 17, 2023 to now33
- Board memberDiane M. Levitan Nov 21, 2023 to now34
- Board memberLeslie Anne Coolidge Aug 4, 2022 to Oct 24, 202235
- Board memberRobert J. Costantino Aug 4, 2022 to now36
- Board memberGregory D. Cash Aug 20, 2019 to Jul 7, 202237
- Board memberScott Mitchell Johnson Aug 20, 2019 to Oct 24, 202238
- Board memberSherry Grisewood Sep 14, 2018 to Feb 21, 201939
- Board memberDavid Don Deming Sep 19, 2018 to May 4, 202240
- Board memberJoseph William Jasper Sep 19, 2018 to now41
- Board memberWesley Hayne Sep 19, 2018 to Sep 19, 201814
- Board memberDavid Edward Merrill Sep 20, 2018 to Feb 21, 201942
- Board memberRobert James Rudelius Sep 20, 2018 to now43
- Board memberPeter Vezmar Oct 17, 2018 to Mar 18, 201944
- Board memberRandall A. Meyer Jun 8, 2015 to Sep 10, 202129
- Board memberDavid B. Masters Mar 28, 2014 to Oct 4, 202145
- Board memberJohn F. Dolan Mar 28, 2014 to Sep 10, 202127
- Board memberJohn Lai Mar 28, 2014 to now15
Former names
- Technologies Scan CorpApr 18, 2011 to May 2, 20143
Timeline
- Sep 22, 20268-K Executive or director change46
- Sep 22, 20268-K Executive or director change47
- Aug 20, 20268-K Regulation FD disclosure48
- Jul 29, 20268-K Ended a material agreement; Regulation FD disclosure49
- Jul 27, 20268-K Change of auditor50
- Jun 25, 20268-K Entered a material agreement; Regulation FD disclosure51
- Jun 11, 20268-K Entered a material agreement; Unregistered sale of shares52
- Apr 17, 20268-K Entered a material agreement; Unregistered sale of shares53
- Mar 27, 20268-K Entered a material agreement; Unregistered sale of shares54
- Mar 16, 20268-K Entered a material agreement; Unregistered sale of shares55
- Mar 4, 20268-K Regulation FD disclosure56
- Jan 29, 20268-K Executive or director change57
- Sep 19, 2018New chief executive Wesley Hayne becomes CEO14
- Mar 28, 2014New chief executive John Lai becomes CEO15
Calendar
When it reported results
- Jun 28, 2024Reported quarterly or annual results58
- Feb 12, 2024Reported quarterly or annual results59
- Nov 14, 2023Reported quarterly or annual results60
- Aug 10, 2023Reported quarterly or annual results61
- Jun 29, 2023Reported quarterly or annual results62
- Feb 9, 2023Reported quarterly or annual results63
- Nov 10, 2022Reported quarterly or annual results64
- Aug 11, 2022Reported quarterly or annual results65
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
327 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 97 major events, 145 insider forms, 39 large holders, 25 other. The latest 20:
- Sep 22, 20268-K EDGAR
- Sep 22, 20268-K EDGAR
- Sep 21, 20264 EDGAR
- Sep 15, 2026SCHEDULE 13D/A EDGAR
- Sep 15, 20264 EDGAR
- Sep 11, 20264/A EDGAR
- Sep 11, 20264/A EDGAR
- Sep 10, 20264 EDGAR
- Sep 10, 20264 EDGAR
- Aug 20, 20268-K EDGAR
- Aug 14, 202610-Q EDGAR
- Aug 5, 2026SCHEDULE 13G EDGAR
- Jul 29, 20268-K EDGAR
- Jul 27, 20268-K EDGAR
- Jul 22, 20264 EDGAR
- Jul 22, 20264 EDGAR
- Jun 29, 202610-K EDGAR
- Jun 25, 20268-K EDGAR
- Jun 11, 20268-K EDGAR
- Jun 11, 20264 EDGAR
The 327 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
159 open-market trades by officers, directors and large owners since October 2021: 159 buys and 0 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 14, 2026 | A.L. Sarroff Fund, LLC10% owner | Buy | 24,888 | $0.69 | $17.2K | Form 4 |
| Sep 10, 2026 | A.L. Sarroff Fund, LLC10% owner | Buy | 10,974 | $0.68 | $7.5K | Form 4 |
| Sep 9, 2026 | A.L. Sarroff Fund, LLC10% owner | Buy | 22,160 | $0.68 | $15.1K | Form 4 |
| Aug 27, 2026 | A.L. Sarroff Fund, LLC10% owner | Buy | 580 | $0.69 | $400 | Form 4 |
| Jun 9, 2026 | A.L. Sarroff Fund, LLC10% owner | Buy | 187,500 | Form 4 | ||
| May 22, 2026 | A.L. Sarroff Fund, LLC10% owner | Buy | 250,000 | $0.40 | $100.0K | Form 4 |
| Mar 23, 2026 | A.L. Sarroff Fund, LLC10% owner | Buy | 24,033 | $0.68 | $16.4K | Form 4 |
| Mar 13, 2026 | A.L. Sarroff Fund, LLC10% owner | Buy | 1,250,000 | Form 4 | ||
| Dec 26, 2025 | A.L. Sarroff Fund, LLC10% owner | Buy | 2,400 | $1.16 | $2.8K | Form 4 |
| Dec 24, 2025 | A.L. Sarroff Fund, LLC10% owner | Buy | 14,632 | $1.09 | $15.9K | Form 4 |
| Dec 16, 2025 | A.L. Sarroff Fund, LLC10% owner | Buy | 7,700 | $1.15 | $8.9K | Form 4 |
| Dec 12, 2025 | A.L. Sarroff Fund, LLC10% owner | Buy | 1,100 | $1.14 | $1.3K | Form 4 |
| Dec 11, 2025 | A.L. Sarroff Fund, LLC10% owner | Buy | 10,000 | $1.17 | $11.7K | Form 4 |
| Dec 10, 2025 | A.L. Sarroff Fund, LLC10% owner | Buy | 6,700 | $1.14 | $7.6K | Form 4 |
| Dec 9, 2025 | A.L. Sarroff Fund, LLC10% owner | Buy | 5,100 | $1.11 | $5.7K | Form 4 |
| Dec 8, 2025 | A.L. Sarroff Fund, LLC10% owner | Buy | 8,154 | $1.05 | $8.6K | Form 4 |
| Dec 5, 2025 | A.L. Sarroff Fund, LLC10% owner | Buy | 21,571 | $1.10 | $23.8K | Form 4 |
| Dec 2, 2025 | A.L. Sarroff Fund, LLC10% owner | Buy | 1,000 | $1.13 | $1.1K | Form 4 |
| Nov 21, 2025 | A.L. Sarroff Fund, LLC10% owner | Buy | 127,250 | $0.95 | $120.9K | Form 4 |
| Nov 20, 2025 | A.L. Sarroff Fund, LLC10% owner | Buy | 20,000 | $1.10 | $22.0K | Form 4 |
All 159 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- A.L. Sarroff Fund, LLCSCHEDULE 13D/A, 15 filings Aug 21, 2023 to Sep 15, 202666
- Alex NazarenkoSCHEDULE 13G, 2 filings Nov 4, 2024 to Aug 5, 202667
- Stanley C. CrudenSCHEDULE 13G/A, 19 filings Jan 28, 2022 to Jan 20, 202668
- John F. DolanSC 13D/A, 1 filing Jun 23, 202269
- John LaiSC 13D/A, 1 filing Jun 23, 202270
- Randall A. MeyerSC 13D, 1 filing Jun 23, 202271
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Vermillion Wealth Management, Inc. | 48,100 | $40.4K | 0.0% | New |
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How PetVivo Holdings, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARPetVivo Holdings, Inc.1
- CIK0001512922
- Employer ID (EIN)99-03635594
- Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; a shell company4
- Incorporated inNevada4
- Fiscal year endsMarch 311
- Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus1
- SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
- Business address5251 Edina Industrial Blvd, Edina, MN 554391
- Phone(952) 217-49521
- Shares outstanding37,950,495 as of Aug 14, 202613
- Public float$12.1M as of Jun 29, 20264
- AuditorStephano Slack LLC, Wayne, Pennsylvania PCAOB ID 3523; no auditor attestation of internal control over financial reporting4
- On EDGAR sinceApr 18, 20111
- Filings694 in all: 4 (228), 8-K (167), 10-Q (45), 3 (26), SC 13G (18), NT 10-Q (16), 10-K (15), 10-Q/A (15)1
All 41 form types
UPLOAD (15), CORRESP (12), 4/A (11), 8-K/A (10), SC 13G/A (10), SC 13D (9), 10-K/A (8), NT 10-K (8), SCHEDULE 13G/A (8), 424B5 (7), DEF 14C (7), PRE 14C (7), PRER14C (7), S-1/A (6), SC 13D/A (5), 5 (4), EFFECT (4), 424B3 (3), DEF 14A (3), DEFA14A (3), S-1 (2), S-8 (2), SCHEDULE 13D/A (2), SCHEDULE 13G (2), 25-NSE (1), 424B4 (1), 8-A12B (1), 8-A12G (1), CERT (1), D (1), POS AM (1), S-3 (1), SCHEDULE 13D (1)
- Latest filingsAnnual report (10-K) Jun 29, 2026
Quarterly report (10-Q) Aug 14, 2026
Proxy statement (DEF 14A) Oct 3, 2023
Latest 8-K (8-K) Sep 22, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, par value $0.001 | PETV | |
| Warrants to purchase Common Stock | PETVW |
From the cover page of the 10-K filed Jun 29, 2026 (Section 12(b) of the Exchange Act).4
Risk factors and legal proceedings
The risks PetVivo Holdings, Inc. names in Item 1A of its 10-K filed Jun 29, 2026: 28 risks under these headings, as written.4
- Risks Relating to Our Financial Condition
- The Company’s failure to meet the continued listing requirements of The Nasdaq Capital Market has resulted in a delisting of its securities.
- We have incurred substantial losses to date and could continue to incur such losses.
- If we are unable to obtain sufficient funding, we may have to reduce materially or even discontinue our business.
- Risks Relating to Our Business and Industry
- We have a limited operating history upon which to base an evaluation of our business prospects.
- We are substantially dependent upon the success of Spryng® and any failure of Spryng® to achieve market acceptance would harm us significantly.
- Our lead product, Spryng®, will face significant competition in our industry, and our failure to compete effectively may prevent us from achieving any significant market penetration.
- We will rely on third parties to conduct studies of our current and new products, and if these third parties do not successfully perform their contracted commitments effectively or substantially fail to meet expected study deadlines, we could be delayed from effectively commercializing our future products.
- Our success is highly dependent on the clinical advancement of our products and adverse results in clinical trials and other studies could prevent us from effectively commercializing our future products
- Our operations rely on third parties to produce our raw materials to produce our products.
- If we experience the rapid commercial growth of Spryng®, we may not be able to manage such growth effectively.
The other 18 risks
- Our Distribution relationships with Vedco and Clipper Distributing are important to our business and if we were to lose our Distribution relationships it would adversely affect our revenues and profitability.
- If our current sales and marketing program is insufficient or inadequate to support the current introduction of our Spryng® product, we may not be able to sell this product in quantities to become commercially successful.
- Our business will depend significantly on the sufficiency and effectiveness of our marketing and product promotional programs and incentives.
- Any damage to our reputation or our brand may materially harm our business.
- If we fail to attract and retain qualified management and key scientific personnel, we may be unable to successfully commercialize our current products or develop new products effectively.
- Natural disasters and other events beyond our control could materially adversely affect us.
- Risks relating to Manufacturing
- We may not be able to manage our manufacturing and supply chain effectively, which would harm our results of operations.
- Risks relating to our Intellectual Property
- Failure to protect our intellectual property could harm our competitive position or cause us to incur significant expenses and personnel resources to enforce our rights.
- We may be subject to intellectual property infringement claims, which could result in substantial damages and diversion of the efforts and attention of our management.
- Risks related to Regulation
- We may be unable to obtain required regulatory approvals for future products timely or at all, and the denial or substantial delay of any such approval could delay materially or even prevent our efforts to commercialize new products, which could adversely impact our ability to generate future revenues.
- Risks relating to our Information Technology
- A failure of one or more key information technology systems, networks, or processes may harm our ability to conduct our business effectively.
- Risks Related to our Company
- Ownership and control of our Company is concentrated in our management.
- The market price of our common stock is highly volatile because of several factors, including a limited public float.
- Our common stock has in the past been a “penny stock” under SEC rules, and if our common stock is deemed to be a “penny stock,” it will be more difficult to resell our securities.
- We are required to comply with certain provisions of Section 404 of the Sarbanes-Oxley Act of 2002, as amended (the “Sarbanes-Oxley Act”) and if we fail to continue to comply, our business could be harmed, and the price of our securities could decline.
- We do not anticipate paying any dividends on our common stock for the foreseeable future.
- The elimination of monetary liability against our directors and executive officers under Nevada law and the existence of indemnification rights held by them granted by our bylaws could result in substantial expenditures by us.
- Our Articles of Incorporation, Bylaws, and Nevada law may have anti-takeover effects that could discourage, delay or prevent a change in control, which may cause our stock price to decline.
Legal proceedings
From time to time, we may become involved in legal proceedings arising in the ordinary course of our business, the resolution of which we do not anticipate would have, individually or in the aggregate, a material adverse effect on our business, financial condition, or results of operations. Refer to Note 9. Commitments and Contingencies – Legal Proceedings, in the Notes to Consolidated Financial Statements set forth in Part II, Item 8. Financial Statements and Supplementary Data of this Annual Report, for further information regarding potential legal proceedings.
The opening of Item 3, Legal Proceedings.4
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15SEC EDGARJohn Lai, Chief executive officer
- 16SEC EDGARJohn Lai, Chair
- 17SEC EDGARDavid B. Masters, President
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28SEC EDGARJohn Lai, Chief operating officer
- 29
- 30SEC EDGARJohn F. Dolan, Secretary
- 31SEC EDGARJoshua David Ruben, Board member
- 32SEC EDGARMichael Eugene Eldred, Board member
- 33
- 34SEC EDGARDiane M. Levitan, Board member
- 35SEC EDGARLeslie Anne Coolidge, Board member
- 36SEC EDGARRobert J. Costantino, Board member
- 37SEC EDGARGregory D. Cash, Board member
- 38SEC EDGARScott Mitchell Johnson, Board member
- 39SEC EDGARSherry Grisewood, Board member
- 40SEC EDGARDavid Don Deming, Board member
- 41SEC EDGARJoseph William Jasper, Board member
- 42SEC EDGARDavid Edward Merrill, Board member
- 43SEC EDGARRobert James Rudelius, Board member
- 44SEC EDGARPeter Vezmar, Board member
- 45SEC EDGARDavid B. Masters, Board member
- 46SEC EDGARExecutive or director change
- 47SEC EDGARExecutive or director change
- 48SEC EDGARRegulation FD disclosure
- 49
- 50SEC EDGARChange of auditor
- 51
- 52
- 53
- 54
- 55
- 56SEC EDGARRegulation FD disclosure
- 57SEC EDGARExecutive or director change
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71